ERBB2 and breast carcinoma: In general, the response to NAC depends on the molecular subtype of breast cancer: the pCR rate for HER2-positive breast cancers approaches 60%; for TNBC ranges from 40 to 50%; and for luminal breast cancers is approximately 12% [6,28,29].